Investor mix
18 investors on record; lead investors include Lilly Asia Ventures, Temasek, Qiming Venture Partners, TF Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 22% |
| Private equity | 9 | 50% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 4 | 22% |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
18 investors on record; lead investors include Lilly Asia Ventures, Temasek, Qiming Venture Partners, TF Capital.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 22% |
| Private equity | 9 | 50% |
| Bank & private debt | 1 | 6% |
| Other / undisclosed | 4 | 22% |